BLCO

16.00

1.84% -0.30

Handel nachbörslich: 16.01 0.01 +0.06%

Bausch Lomb Corp (BLCO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$16.30

Offen:

$16.3

24-Stunden-Volumen:

368.31K

Relative Volume:

0.83

Marktkapitalisierung:

$5.70B

Einnahmen:

$5.21B

Nettoeinkommen (Verlust:

$-211.00M

KGV:

-25.89

EPS:

-0.6179

Netto-Cashflow:

$861.30K

1W Leistung:

+1.78%

1M Leistung:

-2.97%

6M Leistung:

+1.72%

1J Leistung:

+40.72%

1-Tages-Spanne:

$15.93

$16.41

1-Wochen-Bereich:

$15.26

$16.41

52-Wochen-Spanne:

$10.83

$18.91

Bausch Lomb Corp Stock (BLCO) Company Profile

Firmenname

Bausch Lomb Corp

Sektor

Healthcare (1106)

Branche

Medical Instruments & Supplies (56)

Telefon

908-541-5456

Adresse

520 APPLEWOOD CRESCENT, VAUGHAN

Mitarbeiter

13,000

Twitter

Nächster Verdiensttermin

2026-04-29

Neueste SEC-Einreichungen

BLCO's Discussions on Twitter

Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BLCO Bausch Lomb Corp	16.00	5.81B	5.21B	-211.00M	861.30K	-0.6179
ISRG Intuitive Surgical Inc	451.38	160.21B	10.58B	3.00B	2.83B	8.2437
BDX Becton Dickinson Co	144.17	41.62B	21.92B	1.76B	2.63B	6.1223
MDLN Medline Inc	45.32	37.37B	28.43B	1.16B	1.26B	1.4457
ALC Alcon Inc	74.45	35.82B	10.40B	980.00M	1.61B	1.9749
RMD Resmed Inc	207.88	30.38B	5.40B	1.49B	1.78B	10.12

Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-05	Herabstufung	Evercore ISI	Outperform → In-line
2025-12-11	Hochstufung	Citigroup	Neutral → Buy
2025-12-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-10-01	Eingeleitet	Goldman	Neutral
2025-05-02	Bestätigt	H.C. Wainwright	Buy
2025-03-28	Herabstufung	Wells Fargo	Overweight → Equal Weight
2024-12-11	Herabstufung	Citigroup	Buy → Neutral
2024-12-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-10-15	Hochstufung	Evercore ISI	In-line → Outperform
2024-07-10	Eingeleitet	Raymond James	Outperform
2024-05-06	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-01-04	Herabstufung	Evercore ISI	Outperform → In-line
2023-12-12	Eingeleitet	Stifel	Hold
2023-10-03	Fortgesetzt	Evercore ISI	Outperform
2023-05-30	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-03-09	Eingeleitet	Needham	Hold
2022-12-21	Eingeleitet	Barclays	Equal Weight
2022-09-12	Eingeleitet	H.C. Wainwright	Buy
2022-07-26	Eingeleitet	RBC Capital Mkts	Outperform
2022-06-24	Eingeleitet	Evercore ISI	Outperform
2022-06-06	Eingeleitet	Citigroup	Buy
2022-05-31	Eingeleitet	Deutsche Bank	Hold
2022-05-31	Eingeleitet	Goldman	Neutral
2022-05-31	Eingeleitet	Guggenheim	Buy
2022-05-31	Eingeleitet	JP Morgan	Neutral
2022-05-31	Eingeleitet	Jefferies	Buy
2022-05-31	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-31	Eingeleitet	Wells Fargo	Overweight
2022-05-11	Eingeleitet	Cowen	Outperform

Alle ansehen

Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten

May 04, 2026

Bausch & Lomb Earnings: Vision Care Resilience and Pharmaceutical Rebound Lead Off 2026 - Morningstar

May 04, 2026

H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛

May 04, 2026

May 01, 2026

What Bausch + Lomb (BLCO)'s Upgraded 2026 Outlook and Narrowing Losses Mean For Shareholders - Yahoo Finance

May 01, 2026

Bausch & Lomb (BLCO) director receives 1,415 restricted share units - Stock Titan

May 01, 2026

Director at Bausch & Lomb (NYSE: BLCO) granted 1,611 RSUs - Stock Titan

May 01, 2026

Director John Paulson receives 1,375 RSUs in Bausch & Lomb (NYSE: BLCO) - Stock Titan

May 01, 2026

Bausch & Lomb (BLCO) director receives 1,375 restricted share units - Stock Titan

May 01, 2026

A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $16 - Moomoo

May 01, 2026

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Align Tech (ALGN) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail

May 01, 2026

BLCO.CA Stock Price, Quote & Chart | BAUSCH + LOMB CORP (TSX:BLCO) - ChartMill

May 01, 2026

Apr 30, 2026

Bausch & Lomb Corp Q1 2026 Financial Results and Risk Factors – Form 10-Q Highlights - Minichart

Apr 30, 2026

BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating - 富途牛牛

Apr 30, 2026

Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16 - 富途牛牛

Apr 30, 2026

Bausch + Lomb (NYSE:BLCO) Issues Earnings Results - MarketBeat

Apr 30, 2026

A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $21 - 富途牛牛

Apr 30, 2026

Bausch + Lomb Corporation Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 30, 2026

From dry eye to glaucoma, 40+ Bausch + Lomb studies head to Denver - Stock Titan

Apr 30, 2026

BofA raises Bausch & Lomb stock price target on earnings beat - Investing.com UK

Apr 30, 2026